Fibrates and triglyceride metabolism
- PMID: 2044642
Fibrates and triglyceride metabolism
Abstract
Some mechanisms of the triglyceride-lowering effects of fibrates in patients with hypertriglyceridemia are reviewed. One main effect of the fibrates is the stimulation of lipoprotein lipase activities in plasma as well as in adipose tissue. According to this increase in the degradational activity VLDL catabolism is stimulated, as has been demonstrated for VLDL apo B and VLDL triglycerides. In addition, the composition of hypertriglyceridemic LDL is reverted towards normal. Furthermore, the increased degradation via the nonreceptor pathway is decreased by fibrate treatment, thus lowering the atherogenic potential of triglyceride-rich lipoproteins. But additionally the degree of postprandial hypertriglyceridemia is lowered by fibrates.
Similar articles
-
Fibric acids: effects on lipids and lipoprotein metabolism.Am J Med. 1987 Nov 27;83(5B):9-20. doi: 10.1016/0002-9343(87)90866-7. Am J Med. 1987. PMID: 3318457 Review.
-
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.J Lipid Res. 1995 Dec;36(12):2541-51. J Lipid Res. 1995. PMID: 8847480
-
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.Eur J Clin Pharmacol. 1991;40(1):33-41. doi: 10.1007/BF00315136. Eur J Clin Pharmacol. 1991. PMID: 2060543
-
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.Drugs Today (Barc). 2006 Jan;42(1):39-64. doi: 10.1358/dot.2006.42.1.963528. Drugs Today (Barc). 2006. PMID: 16511610 Review.
-
Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.Br J Pharmacol. 1996 Mar;117(6):1155-62. doi: 10.1111/j.1476-5381.1996.tb16710.x. Br J Pharmacol. 1996. PMID: 8882610 Free PMC article.
Cited by
-
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.Drugs. 1996 Nov;52(5):725-53. doi: 10.2165/00003495-199652050-00008. Drugs. 1996. PMID: 9118820 Review.
References
MeSH terms
Substances
LinkOut - more resources
Medical